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Sustained-Release Endotoxin
A Model for Inducing Corneol Neovoscularizorion
William W. Li,* Galen Grayson,* Judah Folkman,t and Patricia A. D'Amore:f:
The rabbit corneal pocket assay is one of the most frequently used systems for the study of angiogene-
sis. This model particularly is useful to identify stimulators of new blood vessel formation. More
recently, however, interest in inhibitors of angiogenesis has grown, and several antiangiogenic agents
have been identified. Investigations of angiogenesis inhibitors require a reliable model for the stimula-
tion of neovascularization. One method was modified to produce corneal neovascularization by implant-
ing into the rabbit cornea a sustained-release polymer containing endotoxin {Escherichia coli lipopoly-
saccharide). The implant was prepared by mixing weighed quantities of endotoxin with ethylene vinyl
acetate copolymer (Elvax) and forming 1-mm3 pellets containing 1%, 7.5%, 15%, 20%, 30%, and 40%
(w/w) of endotoxin. Pure Elvax pellets were implanted as controls. Intrastromal corneal pockets were
created in 92 eyes of male, albino New Zealand rabbits (n = 80), and sterilized endotoxin-copolymer
implants were introduced. The growth rate of new vessels was measured by slit-lamp biomicroscopy.
Endotoxin loads of 15% (n = 40) produced a strong neovascularization response with minimal stromal
edema, with a mean growth rate of 0.21 ± 0.12 mm/day. Loads of 1%, 7.5%, and 20% yielded 0.1 ± 0.03
mm/day, 0.27 ± 0.05 mm/day, 0.30 ± 0.06 mm/day, respectively (n = 8, each group). Higher loads
(30% and 40%; n = 8, each group) produced intense neovascularization, accompanied by severe corneal
edema that obscured accurate measurement of the vessels. Corneal pockets that did not contain poly-
mer implants were avascular. When endotoxin-Elvax pellets were removed, the new vessels regressed
within 2 weeks. This method offers the advantages of consistency and reproducibility over current
models, such as silver nitrate, tumor, silica and thermal burn, for induction of corneal neovasculariza-
tion and provides a reliable system for the study of angiogenesis inhibitors. Invest Ophthalmol Vis Sci
32:2906-2911,1991
Neovascularization is associated with pathologic
processes involving virtually every ocular tissue, in-
cluding proliferative retinopathies, neovascular glau-
coma, and corneal neovascularization. However,
only a few of these conditions respond well to conven-
tional medical therapies. A proposal advanced in
1971' suggested that specific inhibitors of angiogene-
sis could be used to treat pathologic neovasculariza-
tion. Numerous inhibitors of angiogenesis were re-
ported2'3 (including heparin and angiostatic ste-
roids,4"6 a collagenase inhibitor,7 platelet factor IV,3-8
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vitreous-derived inhibitors,910 and several synthetic
compounds.11 Moreover, the angiostatic effect of sev-
eral inhibitors is potentiated by heparin,5 an arylsulfa-
tase inhibitor,12 and sulfated beta-cyclodextrins.1314
As these compounds became available in sufficient
quantity for large-scale animal studies, the testing of
angiostatic drugs to treat ophthalmic diseases became
feasible. However, models for the induction of ocular
neovascularization are difficult to reproduce and
quantify. Previous models of cornea neovasculariza-
tion include intrastromal implants of syngeneic tu-
mors (V2 and Brown-Pearce carcinoma)1516 and
silver nitrate,17 alkali,18 and thermal burns.19 The tu-
mor-implant method generates the most powerful
neovascular response, but it is limited both by incon-
sistent and excessively rapid tumor growth after tu-
mor vascularization. Neovascularization induced by
silica particle implants is similarly difficult to repro-
duce. The burn models are based on injury to the
corneal surface, also difficult to repeat quantitatively;
furthermore, the burns render the cornea susceptible
to microbial keratitis and ulceration.
We developed a model using a sustained-release
Escherichia coli endotoxin implanted into the rabbit
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cornea that offers the advantages of consistency and
reproducibility over the previous inducers of corneal
neovascularization. This model should be useful for
the study of both angiogenesis stimulation and inhibi-
tion.
Materials and Methods
All animals were handled in accordance with the
ARVO Resolution on the Use of Animals in Re-
search. Male albino New Zealand rabbits (4.5-6.5 kg)
were used in all experiments.
Preparation of Sustained-Release Polymers
Polymers were prepared as described earlier.20 Eth-
ylene vinyl acetate copolymer (Elvax; Dupont, Wil-
mington, DE) beads were washed in high-grade abso-
lute ethanol to spectrophotometric purity. The poly-
mer then was dissolved in methylene chloride at room
temperature to a final concentration of 10% (w/v).
The quantity of endotoxin required to achieve
various percent polymer loading was calculated ac-
cording to the following equation:
Desired percent load = X/(0.1 + X)
where X = mg of endotoxin/ml polymer
A weighed quantity of lyophilized endotoxin (E. coli
lipopolysaccharide; Sigma, St. Louis, MO) was mixed
with the 10% Elvax and vortexed vigorously to pro-
duce a homogeneous suspension. An eight-well Te-
flon mold was prechilled on dry ice, with its working
surface covered with a glass plate to prevent conden-
sation in the wells. The endotoxin-Elvax suspension
was delivered through a sterile glass pipette and al-
lowed to polymerize for 10 min. The endotoxin-El-
vax solid was kept at -20°C for 24 hr to complete
polymerization and then desiccated for 48 hr to evapo-
rate residual solvent. Polymer pellets were cut with a
scalpel blade into 1 mm3 weighing 1.3 ± 0.3 mg/pel-
let. Before implantation, polymer pellets were steril-
ized by ultraviolet irradiation.
Corneal Pocket Assay
All surgical procedures were done using sterile tech-
nique. The rabbits were placed under deep general
anesthesia with intravenous pentobarbital (25 mg/kg
body weight) delivered through an ear vein. The cor-
neas were anesthetized before proptosis by topical ap-
plication of 0.5% proparacaine HC1 (Alcon, Hormi-
gueros, Puerto Rico). Intrastromal corneal pockets
were created by making a 1.5-mm central incision to
approximately one half the depth of the cornea (Fig.
1 A). Using an iris spatula, an intrastromal pocket was
created to within 2 mm of the limbus (Fig. IB). Pre-
a
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Fig. 1. Technique for producing corneal pockets. Pellets of sus-
tained-release polymer containing endotoxin were implanted by:
(a) making a 1.5-mm central incision to one-half the depth of the
cornea; (b) using an iris spatula to extend a mid-stromal pocket to a
distance of 2 mm from the limbus; (c) introducing a preweighed
pellet by a glass cannula into the pocket; and (d) reapposing the split
corneal stroma to allow healing.
weighed pieces of the polymer were introduced into
the pocket with a glass cannula and Teflon trochar
(Figs. 1C-D). The eyes were treated with topical eryth-
romycin (Fougera, Melville, NY) and allowed to heal
48 hr postsurgery before observation with a Zeiss slit-
lamp stereoscope every 2 days for 10 days and then
every 4 days for the subsequent 2 weeks.
For slit-lamp biomicroscopy, the rabbit corneas
were anesthetized topically with proparacaine before
proptosis. Vessel growth was documented by measur-
ing the longest vessels in millimeters as the perpendic-
ular distance between the limbus and the growing ves-
sel tip. Vessel density and the presence or absence of
corneal edema were noted qualitatively for each mea-
surement.
Histologic Examination
Two weeks after implantation, the animals were
killed with an overdose of intravenous pentobarbital,
and their corneas were removed and fixed in 10%
phosphate-buffered formalin. The corneas were sec-
tioned, then stained with hematoxylin and eosin and
Masson-trichrome for histologic analysis of inflamma-
tory cells by light microscopy.
Results
Initial screening studies of the corneal response to
polymers containing endotoxin loads of 15%, 30%,
and 40% were conducted. The results of these studies
revealed that the 15% endotoxin-polymer implant
produced negligible corneal edema that lasted only
3-4 days postsurgery. Higher levels of endotoxin
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Fig. 2. Neovascular response 9 days after implantation of sus-
tained-release endotoxin (15%) pellet into the rabbit cornea. The
endotoxin pellet induced an intense localized neovascular from orig-
inating from the limbus and reaching the implant by day 9 post-sur-
gery.
(30% and 40%, n = 16) induced a florid neovascular
response accompanied by severe corneal edema
within 24 hr after implantation. In response to the
15% endotoxin load, vessels sprouting from the lim-
bus into the cornea were visible by slit-lamp biomi-
croscopy by day 4 postsurgery. An intense, well-loca-
lized frond of vessels converged toward and reached
the polymer by day 9 (Fig. 2). Figure 3 shows vessel
length as a function of time after implantation (n
= 40) of 1.0-1.5 mg of 15% loaded endotoxin-poly-
mer implant. The average growth rate for the first 11
days postsurgery, during which the vessels first
reached the polymer, was 0.21 ±0.12 mm/day.
Histologic examination of the corneas 16 days after
implantation of a 15% endotoxin pellet revealed
newly formed vessels growing from the limbus toward
the pocket, the composition of which varied accord-
ing to the corneal region. Immediately surrounding
the pocket, a densely packed rim of inflammatory
cells was present, consisting primarily of heterophilic
polymorphonuclear leukocytes (Fig. 4). In the peri vas-
cular space of newly formed vessels, the infiltrate was
rich in mononuclear cells, with only scattered poly-
morphonuclear cells present. Polymorphonuclear
leukocytes also were found diffusely distributed in the
corneal stroma adjacent to the pocket.
To determine if the neovascular response was dose
dependent, vascularization stimulated by the endo-
toxin-Elvax implants (1.3 mg) with loads of 1%,
7.5%, and 20% was assessed (n = 24). Mean daily
growth rates during the linear growth phase were: 0.1
± 0.03 mm/day, 0.27 ± 0.05 mm/day, and 0.30
± 0.06 mm/day, respectively. Pure Elvax was im-
planted as a control (n = 6) and induced three to four
vessels per cornea in 50% of eyes, with all vessels less
than 0.5 mm in length. Pure Elvax pellets in the re-
maining 50% of controls did not induce neovascular-
ization. The corneas in which pockets were formed
but no polymer was implanted were avascular (n = 6).
Slit-lamp examination of corneas from which en-
dotoxin polymers were removed revealed smaller ves-
sels beginning to thin and regressing within 48 hr.
Vessels that appeared to be less than 0.5 mm in length
and of small caliber regressed the most rapidly and
were no longer visible by 1 week after removal of the
implant. Larger vessels regressed more slowly and, by
2 weeks after pellet removal, were evident primarily
as ghost tracks devoid of erythrocytes.
Discussion
The implantation of a sustained-release Elvax poly-
mer containing a 15% load of endotoxin into rabbit
corneal pockets resulted in well-localized corneal neo-
vascularization, with vessels converging toward the
polymer implant in every case. Newly induced vessels
8 12
DAYS POST SURGERY
16
Fig. 3. Time course of vessel growth in response to 15% endo-
toxin-loaded pellets. Pellets with a 15% load of endotoxin consis-
tently induced corneal neovascularization in rabbit eyes (n = 40),
when vessel length was measured by slit-lamp biomicroscopy. All
corneas remained clear and compact.
4-
r
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Fig. 4. Histologic sections of rabbit
corneas 16 days following implanta-
tion of an endotoxin (15%) pellet (he-
matoxylin-eosin stain), (a) New vessels
(filled with India ink, see arrows) and
an intense inflammatory infiltrate
have reached the corneal pocket (P).
The implant was removed during tis-
sue sectioning (X16). (b) Detail of
above, revealing India ink-filled new
blood vessels, mononuclear cells
with occasional neutrophils dispersed
throughout the stroma, and a densely
packed rim of polymorphonuclear leu-
kocytes immediately adjacent to the
pocket (X40).
remained in a denned sector of the cornea, and the
degree of vascularization was dose dependent. This
method offers the advantages of consistency and re-
producibility over other animal models for corneal
neovascularization such as tumor implants and silver
nitrate, silica, thermal, or alkali burns.
We specified maximal angiogenesis with minimal
corneal edema as the criteria for the ideal endotoxin
load; this was found to be 15%. Loads of 20% or
greater produced severe corneal edema, and the re-
sulting stromal opacity precluded accurate slit-lamp
measurement of the vessel length. Corneas implanted
with polymers containing endotoxin loads less than
15% were clear and compact but had less intense neo-
vascularization. For instance, the rate of neovascular-
ization induced by 7.5% endotoxin loads was greater
on average than those induced by 15% endotoxin
loads. However, vessel density was significantly
greater with the higher endotoxin load. In 50% of the
control corneal implants thin, vascular sprouts en-
tered the cornea but did not grow beyond 0.5 mm in
length and rapidly regressed within 1 week. Corneas
that did not contain any implant were avascular.
When the endotoxin stimulus was eliminated by re-
moving the polymer from the pocket, the corneal ves-
sels regressed. This observation was similar to that of
others, who reported that removal of a tumor extract
from the cornea led to regression of new capillaries,
with subsequent monocyte phagocytosis of desqua-
mated capillary endothelial cells.21
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Our results were consistent with those of previous
studies showing that E. coli endotoxin incites an in-
flammatory corneal infiltrate composed of lym-
phocytes, mononuclear phagocytes, and macro-
phages.22-23 It previously was shown that the presence
of corneal inflammation is not an absolute prerequi-
site for corneal neovascularization.24 However, our
results show that the strength of the inflammatory
stimulus directly correlated with the degree of the an-
giogenesis in this model. Thus, this model induces
angiogenesis secondary to an inflammatory reaction.
Endotoxin-induced neovascularization presumably is
mediated by factors such as basic fibroblast growth
factor released by macrophages.2526 The response
may be amplified by other macrophage products in-
cluding tumor necrosis factor-alpha and transforming
growth factor-beta that also stimulate angiogenesis by
an inflammatory response.27"33
In our studies of angiogenesis inhibitors, we found
the difficulty in quantifying corneal neovasculariza-
tion to be a major obstacle to studying angiostatic
compounds for ophthalmic use. In other models,
such as the intrastromal tumor implant and central
corneal burns, quantitation was difficult because the
vascular response was circumferential and not uni-
form. These limitations restricted the measurement
of neovascularization to fixed, flat-mounted prepara-
tions of treated corneas that could be evaluated by
computer-assisted planimetry or image analysis.3435
This useful but tedious method requires killing the
animal and thus obviates continuous monitoring of
an implant. The endotoxin model addresses this
problem because it yields a localized sector of angio-
genesis defined by the implant and limbal arc, approx-
imately 10-20% of the total corneal circumference. A
consistent degree of neovascularization in this sector
allows daily measurement of the longest vessels and
comparison of angiogenesis-inhibitor effects between
treated corneas and untreated positive control cor-
neas. Blood vessel inhibition and regression therefore
can be documented in the living animal and in flat-
mounted corneal specimens. Furthermore, the dose
dependence of the endotoxin-induced response al-
lows stimulation of both mild and intense corneal neo-
vascularization; this may be used to simulate the spec-
trum of severity of clinically encountered corneal neo-
vascularization.
Key words: polymer, angiogenesis, inflammation, lipopoly-
saccharide, angiogenesis inhibition
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